244 research outputs found

    Infection in Indonesian Population

    Get PDF
    We measured the accuracy of the urine test (RAPIRUN) for detection of Helicobacter pylori infection in Indonesia (Jakarta, Pontianak, and Jayapura) using histology confirmed by immunohistochemistry and/or culture as gold standards. We also used immunohistochemistry to identify CagA phenotype and analyzed H. pylori CagA diversity in Indonesia. The overall prevalence of H. pylori infection in 88 consecutive dyspeptic patients based on the urine test was 15.9 (14/88), 38.1 for patients in Jayapura that had higher prevalence of H. pylori infection than that in Jakarta (9.7, P = 0.02) and Pontianak (8.3, P = 0.006). Overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of RAPIRUN were 83.3, 94.7, 71.4, 97.3, and 93.2, respectively. All of the H. pylori-positive patients were immunoreactive for anti-CagA antibody but not immunoreactive for East Asian specific anti-CagA antibody in all H. pylori-positive subjects. We confirmed the high accuracy of RAPIRUN in Indonesian population. In general, we found less virulent type of H. pylori in Indonesia, which partly explained the low incidence gastric cancer in Indonesia. © 2015 Ari Fahrial Syam et al

    Management of Antithrombotic in Endoscopic Procedures

    Get PDF
    The use of antithrombotic medicine has increased along with the growing number of cardiovascular disease in the world. Endoscopy procedure often done to the patients who use antithrombotic medicine. Eventhough most of endoscopies are safe for those patients, there are some main things related to antithrombotic treatment management that have to be noted such as the kind of antithrombotic that being used, stratification of bleeding risk on the procedure, the risk of future thromboembolic, and the process of antithrombotic treatment re-initiation. So that, patient’s safety in undergoing endoscopy procedure is guaranteed

    COVID-19 treatment during and after recovery: What to expect

    Get PDF
    Currently, there are no clinically specific drug for COVID-19, neither novel treatments nor vaccines. Hospitals and researchers over the world are testing many different therapies on coronavirus-positive patients in an effort to find a potential COVID-19 treatment, a few medications that have been making a buzz in the science community such as remdesivir, hydroxychloroquine and chloroquine, favipiravir, oseltamifir, lopinavir/ritonavir, azithromycin, plasma convalescent, dexamethasone and stem cell
    corecore